These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 8406590)

  • 41. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
    Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
    J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the C3 receptor induced by herpes simplex virus type 1 infection of human epidermal, endothelial, and A431 cells.
    Kubota Y; Gaither TA; Cason J; O'Shea JJ; Lawley TJ
    J Immunol; 1987 Feb; 138(4):1137-42. PubMed ID: 3027170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. gp13 (EHV-gC): a complement receptor induced by equine herpesviruses.
    Huemer HP; Nowotny N; Crabb BS; Meyer H; Hübert PH
    Virus Res; 1995 Jul; 37(2):113-26. PubMed ID: 7483825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H.
    Haque A; Cortes C; Alam MN; Sreedhar M; Ferreira VP; Pangburn MK
    Front Immunol; 2020; 11():1728. PubMed ID: 32849614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
    Kalli KR; Ahearn JM; Fearon DT
    J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
    J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
    Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
    J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
    Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
    Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.
    Weis JJ; Tedder TF; Fearon DT
    Proc Natl Acad Sci U S A; 1984 Feb; 81(3):881-5. PubMed ID: 6230668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The multifunctional role of C3: structural analysis of its interactions with physiological ligands.
    Lambris JD; Müller-Eberhard HJ
    Mol Immunol; 1986 Nov; 23(11):1237-42. PubMed ID: 2950317
    [No Abstract]   [Full Text] [Related]  

  • 54. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
    Nemerow GR; Jensen FC; Cooper NR
    J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complement factor I deficiency in a family with recurrent infections.
    Leitão MF; Vilela MM; Rutz R; Grumach AS; Condino-Neto A; Kirschfink M
    Immunopharmacology; 1997 Dec; 38(1-2):207-13. PubMed ID: 9476132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proliferation of resting B cells is modulated by CR2 and CR1.
    Fingeroth JD; Heath ME; Ambrosino DM
    Immunol Lett; 1989 Jun; 21(4):291-301. PubMed ID: 2527816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.